The National Cancer Institute (NCI) awarded a $954,000 Project Grant (CFDA 93.396 - Cancer Biology Research) to the University of Pittsburgh to investigate how aging promotes the growth of glioblastoma, one of the most lethal forms of cancer. The research aims to leverage insights from the biology of neural stem cells and the molecular circuitry of cancer stem cells to understand how aging creates a tumor microenvironment that supports the survival and proliferation of glioblastoma. The...
This federal Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) supports research to study translation regulation in glioblastoma stem-like cells (GSCs) and its role in hypoxia adaptation. The $107,948 award to Case Western Reserve University aims to develop a better understanding of how translational regulation, as opposed to transcriptional regulation, allows GSCs to adapt to the hypoxic tumor environment and promote glioblastoma growth. The...
This $682,596 Project Grant award from the National Cancer Institute's Cancer Biology Research (CFDA 93.396) program supports research by The University of Texas Southwestern Medical Center to investigate the metabolic mechanisms underlying glioma progression. The project aims to: 1) dissect the molecular basis for metabolic reprogramming and aberrant metabolite secretion in high-grade gliomas, 2) determine the impact of these metabolic changes on the tumor microenvironment and neuronal...
This federal Project Grant award in the amount of $1,271,780.00 was provided by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395). The funding supports research by the University of Pittsburgh to develop small molecule adaptors for precisely controlling and reprogramming universal chimeric antigen receptor (CAR) T cell therapies. Specifically, the research aims to: 1) Create small molecule adaptors that can target multiple antigens on tumor cells and...
The National Cancer Institute (NCI) awarded a Project Grant (CFDA 93.396 - Cancer Biology Research) totaling $585,931 to the University of Pittsburgh to conduct research on evaluating and selecting representative cancer models for precision medicine. The key objectives are to: (1) identify and clinically annotate prevalent subclones and tumor microenvironment cell types in breast cancer; (2) perform subclone-based congruence and selection for cancer models; and (3) decipher temporal changes in...
This $238,722 federal Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) supports research at the Sloan-Kettering Institute for Cancer Research to investigate the role of mutagenic DNA repair pathways in the persistence and acquired drug resistance of cancer cells. The key objectives are to: (1) study persistence mechanisms in BRCA1/2-mutant cancer cells treated with PARP inhibitors, (2) examine how mutagenic DNA repair via...
The National Cancer Institute (NCI) awarded a $201,172 Project Grant (CFDA 93.398 - Cancer Research Manpower) to Duke University to conduct research on using cell-free DNA methylation patterns as a non-invasive biomarker for glioblastoma, an aggressive and difficult-to-treat brain cancer. The research aims to overcome key challenges in understanding glioblastoma tumor biology and monitoring disease progression, including limitations of current diagnostic methods that rely on invasive surgical...
This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $162,486 to the University of Pittsburgh to conduct research on the functional consequences of high glucose culture on adoptive T cell therapies for cancer. The key objectives are to: 1) Identify cellular proteins that are differentially O-GlcNAcylated in T cells cultured in high glucose, and determine if inhibiting O-GlcNAcylation can restore cytokine production, antitumor immunity, and...
This Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) totaling $451,996 aims to develop a high-throughput screening platform to identify and validate novel drug therapies targeting migrating and treatment-resistant glioblastoma (GBM) cancer cells. The key products and services to be delivered include: Employing an ex vivo integrated high-throughput platform for quantitative cellular/molecular analysis and biophysical assessment of...
This Project Grant award from the National Cancer Institute (NCI) under the CFDA 93.396 Cancer Biology Research program provides $249,000.00 over 3 years to The Trustees of the University of Pennsylvania to conduct research on decoding the evolution and progression of glioma, an incurable type of brain cancer. The key products and services to be delivered through this funding include: Defining how somatic mutations dysregulate transcriptional patterns and dictate glioma cell lineage structure...
This $552,968 Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) supports research conducted by the University of Pittsburgh to investigate the role of tRNA modifications in the regulation of cancer stem cells in glioblastoma. The research aims to provide molecular insights into how altered tRNA modifications in cancer stem cells impact translational reprogramming and drive oncogenic processes in glioblastoma, a highly lethal form of brain cancer. The award period runs from September 21, 2024 to March 31, 2027. The findings from this research may inform the development of novel therapies for glioblastoma.